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Abstract
Background: For the majority of rare clinical missense variants, pathogenicity status cannot currently be
classified. Classical homocystinuria, characterized by elevated homocysteine in plasma and urine, is caused by
variants in the cystathionine beta-synthase (CBS) gene, most of which are rare. With early detection, existing
therapies are highly effective.
Methods: Damaging CBS variants can be detected based on their failure to restore growth in yeast cells
lacking the yeast ortholog CYS4. This assay has only been applied reactively, after first observing a variant in
patients. Using saturation codon-mutagenesis, en masse growth selection, and sequencing, we generated a
comprehensive, proactive map of CBS missense variant function.
Results: Our CBS variant effect map far exceeds the performance of computational predictors of disease
variants. Map scores correlated strongly with both disease severity (Spearman’s ϱ = 0.9) and human clinical
response to vitamin B6 (ϱ = 0.93).
Conclusions: We demonstrate that highly multiplexed cell-based assays can yield proactive maps of variant
function and patient response to therapy, even for rare variants not previously seen in the clinic.
Background
Rapid development of high-throughput sequencing tech-
nology has made it feasible to sequence the genome of
every human. However, for personalized diagnostic sur-
veillance and therapy, timely and accurate methods to
interpret the clinical impact of genetic variants are needed.
Over 138,000 exomes have been collected in the Genome
Aggregation Database (gnomAD) [1, 2] and 4.6 million
coding variants have been discovered. Among these
discovered coding variants, 99% are rare, having a minor
allele frequency (MAF) below 0.5%. Although statistical
association methods have identified many common
variants that correlate with (and in some cases cause) hu-
man disease, correlational methods are typically futile for
rare variants. In ClinVar [3], the majority of interpreted
missense variants are annotated as “variants of uncertain
significance” (VUS) [4, 5].
Diverse computational and experimental methods have
been developed to predict the functional impact of rare
coding variants. Many computational methods can score all
possible missense variants proactively and thus provide
supporting evidence for variant interpretation immediately
upon variant discovery. However, computational predic-
tions were found to identify fewer than 20% of pathogenic
variants when used at stringent thresholds where > 90% of
pathogenic variant predictions were correct [6]. At more
permissive thresholds that detect 90% of pathogenic vari-
ants, fully ~ 30% of pathogenicity predictions were errone-
ous [6]. More accurate predictions can come from
experimentally interrogating the functionality of each vari-
ant [6], but this one-at-a-time approach is prohibitively la-
borious and time consuming. Even where done, these
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experimental assays have necessarily been reactive, i.e., with
results that lag far behind the first clinical presentation.
Variant effect (VE) mapping [7, 8] is a strategy for test-
ing the function of a large number of variants in a single
experiment. A VE map provides a look-up table for func-
tionality of coding variants in disease-associated genes, po-
tentially providing strong evidence that can be collected in
advance of the first clinical observation of a patient vari-
ant, so that it is immediately available to assist clinical
variant interpretation [9, 10], meeting a clinical need that
is particularly acute for rare and personal variants found
via sequencing. Although experimental VE maps generally
contain some missing data, a recently published VE map-
ping framework used machine learning to impute missing
data so that, given a critical mass of experimental data,
missing values could be filled in with accuracy ap-
proaching that of experimental measurements [11].
Human cystathionine β-synthase (CBS) is a cytosolic en-
zyme that catalyzes the first step in the transsulfuration
pathway—condensation of serine and homocysteine to yield
cystathionine—thus eliminating the toxic metabolite homo-
cysteine [12]. Through alternative reactions, CBS also pro-
duces hydrogen sulfide, a gaseous signaling molecule [13,
14]. CBS forms homotetramers and contains heme as a
possible redox sensor and/or folding scaffold, pyridoxal 5′-
phosphate (PLP; the active form of vitamin B6) as a cofactor
necessary for catalytic function, and binds S-adenosyl-
methionine (AdoMet) as an allosteric activator repressing
the effect of the C-terminal autoinhibitory domain [15].
Each CBS monomer has a modular structure: An N-
terminal heme-binding domain is directly followed by a
highly conserved catalytic domain of 311 amino acids
(aa) in length, which contains the binding site for PLP,
including lysine 119, which forms a covalent bond with
the ligand. A short (31 aa) linker connects the catalytic
domain to a regulatory domain comprised of two
AdoMet-binding motifs [16]. Although the exact con-
formation in which CBS forms its tetrameric complexes
is not yet known, as crystallographic analysis has thus
far succeeded only for artificial dimeric structures, a po-
tential model has been described [17]. The majority of
the CBS sequence is strongly preserved across a billion
years of evolution, with the catalytic domain showing
the strongest conservation between human and yeast.
The AdoMet-binding regulatory domain is slightly less
conserved. While this domain is present in yeast, it is ab-
sent in some species such as the worm Caenorhabditis
elegans. The N-terminal half of the linker that connects
the two domains is conserved almost as strongly as the
catalytic domain, while the C-terminal half is only con-
served across vertebrates. Interestingly, yeast carries an
11 aa insertion in the linker, rendering it approximately
one third longer than its human counterpart. Finally,
the N-terminal heme-binding motif is only partially
conserved in some vertebrates and is not present in
yeast.
Classical homocystinuria (MIM #236200) [18] is an auto-
somal recessive disorder of methionine metabolism mani-
fested by abnormal accumulation of total homocysteine in
blood, increased excretion of homocysteine in urine, vari-
ably elevated methionine levels in blood, and simultaneous
decrease of plasma cystathionine. The disease was discov-
ered in 1962 [19] and soon after was shown to be caused
by a deficiency of CBS activity in the liver [20]. Since the
identification of the first disease-causing CBS variants [21],
several hundred alleles have been identified in homozygous
or compound-heterozygous homocystinuria patients [22],
many of which have been further genetically and biochem-
ically characterized [23–28], yielding ~ 200 annotated
pathogenic variants [3, 29]. About 13% of the variants
deposited in the CBS Mutation Database [22] are genomic
deletions, frameshift mutations, premature termination co-
dons, or missplicing variants, some of which affect CBS
mRNA stability via nonsense-mediated decay (NMD) [30],
while others affect protein folding or biochemical function.
However, the majority of these variants (about 87%) are
missense variants. Missense variants may affect catalytic
function with only minor conformational changes or, sub-
stantially more frequently, lead to misfolding amenable to
in vitro correction by chemical chaperones or the presence
of cofactors [23–26, 31–34]. Regardless of the underlying
molecular mechanism, most pathogenic variants yield sub-
stantially decreased or null activity of CBS. By contrast,
missense variants in the C-terminal domain are mechanis-
tically intriguing. Characterization of several expressed mu-
tations in crude extracts or after purification revealed
normal or supraphysiological activity, abnormal AdoMet
regulation, and conformational rigidity [21, 22, 32]. How-
ever, the small minority of CBS deficiency patients carrying
such mutations exhibit high plasma concentrations of total
homocysteine and clinical symptoms indistinguishable from
patients with variants in the catalytic domain. Two major
forms of this disease have been described. Roughly half of
the patients suffer from a severe CBS deficiency which
manifests in childhood by lens dislocation (luxation), skel-
etal abnormalities resembling Marfan syndrome, thrombo-
embolism, and neuropsychiatric problems. This type of
disease usually does not respond to vitamin B6 treatment;
however, early initiation of therapy with low methionine
diet and/or betaine in the newborn period prevents most of
the clinical complications [35]. The other half of the pa-
tients suffer from the milder form of disease, which typic-
ally manifests by thromboembolism in adulthood and
which responds to vitamin B6 treatment [35–37]. Although
the clinical efficacy of vitamin B6 and its effect on de-
creasing plasma total homocysteine are well established,
the underlying mechanism is still unclear. The possible ex-
planations include increased stability of fully PLP-
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saturated mutant enzymes and most likely a chaperoning
effect of co-translationally present PLP on susceptible mu-
tations [15].
The population frequency of severe early-onset CBS
deficiency ranges from 1 in 60000 to 1 in 900000 be-
tween countries, and the worldwide birth frequency
of clinically ascertained patients was estimated to be
1:122000 [38]. However, homocystinuria may be more
frequent in specific populations (1:1800 in Qatar) and
molecular epidemiological studies suggest a higher
frequency of the adult vitamin B6-responsive form
[36, 37, 39–42].
Since only early diagnosis and timely therapy can ef-
fectively prevent long-term complications in patients
with homocystinuria, many newborn screening programs
worldwide target CBS deficiency [43]. Screening by
determining total homocysteine (tHcy) in dried blood
spots is only occasionally performed given the need for a
reduction step prior to LC-MS/MS assay and associated
costs [42]. Therefore, CBS deficiency is usually sought
by screening for elevated methionine concentration and
subsequent testing for tHcy [44]. Unfortunately, screen-
ing newborns for elevated methionine concentrations
misses some vitamin B6-non-responsive patients and a
large proportion of vitamin B6-responsive patients [35,
44]. It has not been shown whether future newborn
screening programs based on genome sequencing could
improve the early detection of homocystinuria.
Yeast complementation assays can identify pathogenic
alleles with high accuracy [6]. The human CBS gene can
complement growth defects in cys4Δ yeast deletion
mutants [45, 46], and this assay can also be used to test
whether variants are vitamin B6-dependent [47–50]. Here
we adapt this complementation assay to our recently de-
scribed VE mapping framework and use it to generate
comprehensive functional maps of CBS missense variation
with low or high levels of vitamin B6. We find that scores
from the resulting VE maps can identify functional vari-
ation in CBS. Moreover, in an independent patient cohort,
patient CBS activity scores derived from the VE map cor-
relate strongly with the age of onset, disease severity, and
response of CBS-deficient patients to vitamin B6 therapy.
Methods
Strains and plasmids
The Saccharomyces cerevisiae strain (MATα cys4Δ::
KanMX his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0), used as a host
for the CBS variant library, was derived from the
yeast knockout collection [51]. The Gateway destin-
ation vector pAG415GAL-ccdB (CEN/ARS-based,
GAL1 promoter, and LEU2 marker) was purchased
from Addgene and served as the yeast expression vec-
tor. The CBS open reading frame (ORF) clone was
obtained from the Human ORFeome v8.1 library [52],
corresponding to UniprotKB accession P35520.
Constructing a codon-randomized CBS variant library
A library of CBS variants was constructed using an oligo-
directed codon-randomization mutagenesis method (Pre-
cision Oligo-Pool based Code Alteration or POPCode)
[11]. Details are described below, with some technical
advancements that decrease the frameshift mutation rate
and thus render the method suitable for mutagenizing lar-
ger genes. An oligonucleotide with length between 28 and
38 bases was designed to target each codon in the CBS
ORF, such that the targeted codon is replaced with an
NNK-degenerate codon (a mixture of all four nucleotides
in the first and second codon positions, and a mixture of
G and T in the third position) using the PopCode oligo
suite webtool [11]. The 550 oligos were synthesized
then combined into a single equimolar pool. A uracil-
doped wildtype template was generated by PCR-
amplifying the ORF as follows: A 50 μl PCR reaction was
set up containing 25 μl 2X Kapa Uracil+ ReadyMix, 2.5
mM dUTP, 10 μM forward and reverse oligos, and 1 ng
template DNA. Thermal cycler conditions are as follows:
98 °C for 5min, 30 cycles of 98 °C for 15 s, 60 °C for 60 s,
and 72 °C for 180 s. A final extension was performed at
72 °C for 5 min. Uracilated amplicon was gel-purified
using the 1% agarose gel at 80 V for 90min, and the bands
cut out and purified using a QIAquick Gel Extraction Kit
(QIAGEN). The final elution volume was 30 μl TE or
ddH2O. The mutagenesis oligo pool was phosphorylated
as follows: A 50 μl reaction containing 10× PNK buffer
(NEB), 300 pmol oligos, 10mM ATP, and 10U poly-
nucleotide kinase (NEB) was incubated at 37 °C for 2 h.
The reaction was used directly in the subsequent POP-
Code reaction. The uracil-doped templates were then
mixed with the phosphorylated oligonucleotide pool. Oli-
gos were annealed to the template by heating the mixture
to 95 °C for 3min and then cooled to 4 °C. Gaps between
annealed oligonucleotides were then filled with KAPA
HiFi Uracil+ DNA polymerase followed by nick-sealing
with T4 DNA ligase (New England Biolabs; NEB). After
degradation of the uracil-doped wildtype strand using
uracil-DNA-glycosylase (UDG; NEB), the mutated
strand was amplified with attB-site-containing primers
and subsequently transferred en masse to a donor vec-
tor via the Gateway BP reaction (Thermo-Fisher Scien-
tific) to generate a library of entry clones. To enable
yeast expression, the library was further transferred to
pAG415-ccdB by en masse Gateway LR reaction and
transformed into the S. cerevisiae cys4Δ mutant strain.
To maintain the complexity of the library, plasmids
were purified from > 100,000 clones at each transferring
step and ~ 1,000,000 yeast transformants were pooled
to form the host library.
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High-throughput yeast-based complementation
The yeast-based functional complementation assay for
CBS function has been well established for characterizing
individual variants [45, 46, 50]. Details are provided here
for high-throughput complementation screening: Plasmids
extracted from a pool of > 100,000 Escherichia coli clones
were transformed into the S. cerevisiae cys4 mutant strain
yielding ~ 1M total transformants. Plasmids were pre-
pared from two replicates of ~ 1 × 108 cells and used as
templates for the downstream tiling PCR (two replicates
of non-selective condition). Selective media were made
with yeast nitrogen base lacking all vitamins and amino
acids (USBiological). All other vitamins except vitamin B6
were added at standard concentrations [50] and vitamin
B6 was supplemented at three different concentrations: 0,
1, and 400 ng/ml. Histidine, uracil, and lysine were added
to relieve auxotrophies in the mutant strain, and 2% gal-
actose was used as a carbon source to induce GAL1-pro-
moter-driven expression. For each of the three pooled
complementation assays (each using a different concentra-
tion of vitamin B6), ~ 4 × 10
8 cells were inoculated into a
200-ml selective medium for each of two replicates. In
parallel, plasmid expressing the wildtype ORF was simi-
larly transformed to the S. cerevisiae cys4 mutant strain in
selective media. Each culture (with two biological replicate
cultures for both the selective and non-selective condi-
tions) was grown to full density (5–6 doublings) while
shaking at 30 °C. Plasmids extracted from ~ 1 × 108 of cells
of each culture were used as templates for the down-
stream tiling PCR.
Detecting variant effects on fitness using TileSeq
For each plasmid library, the tiling PCR was performed
in two steps: (i) the targeted region of the ORF was amp-
lified with primers carrying a binding site for Illumina
sequencing adaptors and (ii) each first-step amplicon
was indexed with an Illumina sequencing adaptor in the
second-step PCR. We performed paired-end sequencing
on the tiled regions across the ORF in two separate
sequencing runs with an average sequencing depth of ~
2 million reads each. All raw sequencing reads were
mapped to CBS using bowtie2 [53] to generate align-
ment files for both the forward and reverse reads. The
tileseq_package software [54] was used to parse the
alignment files and count the number of codon changes
that had been seen on both strands in the paired-read
data. The counts for each mutation in each tiled region
were subsequently normalized by the corresponding
sequencing depth to obtain an “allele frequency” for that
mutation.
Scoring fitness and vitamin B6 remediability
Each sequencing experiment contained not only libraries
derived from selective and non-selective pools, but also
libraries derived from wildtype amplicons, enabling esti-
mation of the component of each mutation’s observed
allele frequency in the pool that was derived from PCR
errors during library preparation or sequencing errors.
After filtering out variants for which selective or non-
selective allele frequencies were lower than a level of
three standard deviations above the corresponding (false
positive) wildtype allele frequencies, data from equiva-
lent codons for each amino acid change were joined.
Then, the allele frequencies observed in the wildtype
control libraries were subtracted from the allele frequen-
cies of the non-selective and selective conditions re-
spectively. Then, an enrichment ratio (Φ) was calculated
for each mutation based on the adjusted selective- and
non-selective-condition allele frequencies.
A maximum a posteriori estimate of the error (σ) in
each enrichment ratio was derived via a weighted aver-
age of the observed variance and the a priori estimate of
σ, according to the error regularization procedure previ-
ously described by Baldi and Long [52]. We used two
pseudocounts, so that the observed variance was given
weight n/(n + 2), based on having n replicates, and the
prior variance was given weight 2/(n + 2). The prior esti-
mate of σ is based on an overall regression of the coeffi-
cient of variation values against sequencing coverage
and fitness values.
A fitness score (sMUT) was calculated for each variant as
ln(ΦMUT/ΦSTOP)/ln(ΦSYN/ΦSTOP), where ΦMUT is the en-
richment ratio calculated for each variant, ΦSTOP is the
median enrichment ratio of all nonsense variants, and
ΦSYN is the median enrichment ratio of all synonymous
variants, such that sMUT = 0 when ΦMUT =ΦSTOP and
sMUT = 1 when ΦMUT =ΦSYN. Well-measured variants
were selected by applying two filters: The allele frequency
in the pre-selection library must be greater than 0.005%
(to avoid undersampling) and standard error must be less
than 0.2.
A vitamin B6 remediability (delta) score was calculated as
the difference between fitness scores at high (400 ng/ml)
and low (both 0 and 1 ng/ml, with fitness scores averaged
due to high agreement between these screens, see the
“Results” section for details) vitamin B6 concentrations.
To produce a complete variant effect map, missing
values were estimated by imputation as previously de-
scribed [11, 55]. Briefly, the imputation machine learning
model was trained on the fitness scores of the experi-
mentally well-covered variants using the gradient-
boosted tree (GBT) method [56] as implemented by the
XGBoost package [57]. The features used in the model
included confidence-weighted averages of other variant
scores at the same position, confidence-weighted aver-
ages of the scores for the 3 and 4 most similar amino
acid changes (according to BLOSUM distance), precom-
puted PolyPhen-2 [58] and PROVEAN [59] scores,
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chemical and physical properties of the wildtype and
substituted amino acids, and protein structure-related
information. Final variant effect maps use scores that
were refined using the weighted average of imputed and
measured values (weighting by the inverse-square of
estimated standard error in each input value).
To estimate agreement with previous individual yeast
complementation assay data [50, 60], only well-
measured values were used. Of the 40 variants for which
our map could be compared against assays made in
Mayfield et al., 36, 33, and 35 variants were well-
measured for the 0, 1, and 400 ng/ml vitamin B6 condi-
tions, respectively. Of 206 variants measured in Wei
et al., 179 were well-measured in our study. All other
analyses used the final imputed and refined map.
Classifying vitamin B6-remediable and non-remediable
variants
Using the fitness score distribution of all synonymous vari-
ants as an empirical null distribution, FDR-adjusted p
values were assigned to all missense variants. The fitness
score corresponding to FDR= 5% was determined to be
0.60, so that missense variants for which the upper end of
the 95% confidence interval of their fitness scores was less
than 0.60 were classified as deleterious variants. Then, for
each variant that was deleterious in the low vitamin B6 con-
dition, a delta fitness score (high vitamin B6 − low vitamin
B6) was calculated. Using the delta fitness score distribution
of all nonsense variants as an empirical null distribution,
FDR-adjusted p values were assigned to all missense vari-
ants and a delta fitness score threshold (0.22, corresponding
to FDR= 5%) was used to identify vitamin B6-remediable
variants. Missense variants for which the lower end of the
95% confidence interval of their delta fitness scores was
greater than 0.22 were classified as vitamin B6 remediable.
Relating fitness score and enzyme activity
A previous study [23] measured the enzyme activity of
CBS variants expressed in E. coli. Of the 27 missense
variants with measured activity, the 24 that were well
measured in this study were selected to investigate the
relationship between our fitness scores and enzyme
activity. More specifically, we examined the correlation
between our high vitamin B6 fitness scores and relative
CBS enzyme activity (variant activity divided by wildtype
activity) with AdoMet at 37 °C. A Michaelis-Menten
curve (of the form y = x/(x + k), where y is the fitness
score, x is the relative enzyme activity, and k is a con-
stant) was fitted to describe the non-linear relationship
between fitness and activity.
A test set of disease- and non-disease-associated variants
To define a set of disease-associated CBS variants, we
considered 86 unique missense variants in the CBS
mutation database [22] that were not linked to a second
variant in the same allele. We next reviewed the relevant
literature, accepting only the 74 disease variants that we
considered to be high confidence. Of these, 71 fell into
the catalytic domain and 3 fell into the regulatory do-
main (Additional file 1: Table S1). Obtaining a set of
non-disease-associated variants was more problematic,
as the ClinVar database contained no missense variants
annotated as “benign” and only one annotated as “likely
benign.” As a proxy set of non-disease-associated vari-
ants, we therefore selected all CBS missense variants
deposited in gnomAD [1, 2] which (i) had no annotated
disease association or experimental evidence of func-
tional impact and (ii) have been observed in at least two
individuals (Additional file 1: Table S1). All CBS variants
from gnomAD that met these criteria were rare, with
minor allele frequency less than 0.005. The positive and
negative reference variants from these sets were then
divided into subsets for the catalytic and regulatory
domains and analyzed separately.
Phenotypes from a cohort of homocystinuria patients
All patients have been followed in the Metabolic Center
in the Department of Pediatrics and Adolescent Medi-
cine at the General University Hospital in Prague. The
clinical, biochemical, and molecular genetic data were
obtained during routine care, and patients gave their in-
formed consent for DNA analysis. Plasma CBS activity
was measured within a research project after obtaining
patient informed consent, which also included consent
for publication of clinical, enzymatic, and molecular
genetic data (approval of the Ethics Committee 1194/13
S-IV).
To assess the clinical severity and vitamin B6 responsive-
ness of CBS deficiency, we developed a semi-quantitative
scoring system based both on tHcy changes after vitamin
B6 administration and on the need for additional therapy.
Non-responsive patients, requiring a low methionine diet
and betaine supplementation (regardless of vitamin B6
therapy), were assigned a vitamin B6 responsiveness score
of 1. Partially responsive patients, in need of both large
doses of vitamin B6 and a low methionine diet, were given
the score 2. Fully responsive patients requiring only vita-
min B6 at a dose above 0.5 mg/kg/day to yield tHcy <
50 μmol/L received a score of 3. Extremely responsive
patients, requiring vitamin B6 at a dose below 0.5 mg/kg/
day to yield tHcy < 50 μmol/L, were given a vitamin B6
responsiveness score of 4.
Disease severity was scored according to the presence
of typical clinical complications at the time of diagnosis
or during follow-up in poorly compliant patients and
could not be determined in two patients detected by
newborn screening. Patients showing no symptoms at
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the time of diagnosis (i.e., detected by screening family
members of patients with diagnosed CBS deficiency)
received a severity score of 5. Patients with mild disease
(thrombosis in any vascular bed with no other symptoms)
received the score 4. Patients with moderate disease (con-
nective tissue involvement with or without thrombosis)
were assigned a score of 3. Those with borderline severity
(mild cognitive impairment with good social outcome,
regardless of other somatic complications) were given a
score of 2. Severe disease patients (having severe neuro-
psychiatric complications including poor social outcome,
regardless of other somatic complications) were defined to
have severity score 1.
In this cohort, 8 variants were represented once, 4
variants were represented 2–3 times, 4 variants were
represented 6–7 times, and 1 variant (p.Ile278Thr)
was represented 20 times. To limit the impact of re-
current variants on our analysis, we iteratively re-
moved the patient with the most common variant X
until no variant appeared more than three times in
the reduced cohort. To select among multiple patients
with variant X, we first preferentially removed pa-
tients with variants occurring in cis with X (thus fa-
voring retention of patients with one variant per
allele) and next preferentially removed patients with a
nonsense, frameshift, or unknown variant in trans (fa-
voring retention of patients with a non-X missense
variant in trans, to favor diversity of missense variants
in the cohort), and patients carrying nonsense or
frameshift variants in both alleles.
Calculating variant effect scores for patient diploid
genotypes
To calculate diploid variant effect scores for each pa-
tient, we modeled the fitness scores (which range from 0
for null variants to 1 for wildtype-like fitness) for combi-
nations of in cis variants as the product of the individual
fitness scores and summed the two allele scores. For
example, for a patient with genotype p.[X];[Y;Z], we
would assign diploid fitness ɸdiploid = ɸX + ɸYɸZ. Where
phasing was not confirmed, we assumed variants were in
trans, as CBS deficiency is a recessive trait and patients
clearly exhibited biochemical features and clinical symp-
toms of the disease.
Results
To provide a proactive resource to inform the rapid in-
terpretation of genetic variation in CBS, we sought to
test all possible missense variants of CBS for functional
effects and vitamin B6 remediability. We therefore reim-
plemented a previously validated humanized yeast model
[45–48, 50], confirming that expression of human CBS
from the hORFeome collection restores the ability of a
yeast cys4Δ strain to grow without supplementation of
glutathione (which provides a source for cysteine that
circumvents the need for synthesizing cystathionine; see
Additional file 2: Figure S1). Coupling this functional
complementation with our recently developed framework
for exhaustively mapping functional coding variants, we
attempted to test the functional impact as well as the
Fig. 1 Production of a CBS variant effect map. a Workflow for generating the CBS variant effect maps using low or high levels of vitamin B6 and
inferring total enzyme activities for patients. b, c Distributions of experimentally determined fitness scores of stop codon, synonymous, and
missense variants with low (b) or high (c) levels of vitamin B6. d Comparison of the distribution of delta scores for missense variants with the null
distribution (delta scores for nonsense and synonymous variants)
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vitamin B6 remediability of all possible missense CBS vari-
ants in parallel (the overall scheme is described in Fig. 1a).
Proactive maps of missense variant function for CBS
First, we constructed a library of CBS variants using a
previously described codon replacement mutagenesis
method [11]. The variant library, initially generated as a
pool of amplicons, was transferred en masse into the
appropriate yeast expression vector via two steps of re-
combinational subcloning. The resulting library of vari-
ant expression clones was then transformed en masse
into the yeast cys4 mutant strain. Sequencing confirmed
that mutagenesis resulted in an even distribution of vari-
ants across the coding sequence, with the number of
amino acid changes per clone following a Poisson distri-
bution with an estimated mean of 2.65 (Additional file 2:
Figure S2).
Next, pools of transformed yeast cys4 mutant strains
were grown competitively in selective medium (lacking
cysteine and its upstream metabolite glutathione) sup-
plemented with low (0 and 1 ng/ml) or high (400 ng/ml)
concentrations of vitamin B6. Allele frequencies of CBS
variants before and after selection were determined by
next-generation sequencing. We used the TileSeq ap-
proach [11], sequencing a tiling set of ~ 100 nucleotide
segments amplified from the pool. We sought to minimize
base-calling errors (which can complicate quantitation of
low allele frequency variants within a pool) by sequencing
both forward and reverse strands of each template cluster
on the flow cell and only accepting variants for which the
complementary variant on the opposite strand is also seen.
Sequencing was performed such that both forward and
reverse strands of each nucleotide position were covered
by ~ 2M reads. In the pre-selection pool, this sequencing
detected 83% of all possible missense variants,
and 94% of the amino acid substitutions that can be
achieved via a single-nucleotide variant (SNV) (Add-
itional file 2: Figure S2C). Fitness scores were calcu-
lated for each amino acid substitution based on post-
selection changes in allele frequency under both low
and high vitamin B6 conditions (see the “Methods” sec-
tion), yielding initial VE maps for CBS. To consider only
fitness scores where allele frequencies were high enough
to be accurately measured, we kept only the ~ 50% of
codon substitutions (corresponding to 75% of amino
acid substitutions) with a pre-selection allele fre-
quency above 0.005% (see the “Methods” section,
Additional file 2: Figure S2C).
Fitness scores from the resulting VE maps were strongly
correlated between replicates (Pearson correlation coeffi-
cient (PCC) ranging from 0.86 to 0.94, Additional file 2:
Figure S3). Correlation was also strong with the relative
growth rates previously determined in single-variant growth
assays [50] with PCC values up to 0.8 (Additional file 2:
Figure S4A-C). Our results also showed weaker but still-
significant correlation with another single-variant analysis
[60] (Additional file 2: Figure S4D). Because fitness scores
were highly correlated (PCC = 0.97) between the two
screens with low levels of vitamin B6 (0 and 1 ng/ml), we
combined these two datasets to generate a single set of
“low vitamin B6” fitness scores (Additional file 2: Figure
S4E). We also calculated a regularized standard error of
each score based on the agreement between replicates as
well as a prior informed by sequencing coverage [11, 61].
97.7% of scores had an estimated regularized standard error
of less than 0.2 (Additional file 2: Figure S5). We filtered
each map further to consider only scores below this error
threshold. After filtering, 59.8% of all possible missense
amino acid substitutions and 60% of all SNV-accessible
amino acid substitutions were well measured in the low
vitamin B6 map (Additional file 2: Figure S2C). Similarly,
58.2% of all missense variants and 59.6% of SNV-accessible
substitutions were well measured in the high vitamin B6
map.
Synonymous variants and nonsense variants each exhib-
ited unimodal fitness score distributions that were well
separated from one another (Fig. 1b, c). The separation
was slightly more pronounced in the regulatory domain
(AUPRC = 0.97) than in the catalytic domain (AUPRC =
0.94) (Additional file 2: Figure S6). Missense variants
under both selection conditions showed bimodal distribu-
tions (Fig. 1b, c). We also calculated a “delta” fitness score
(high vitamin B6 − low vitamin B6 fitness score) for each
variant. The distribution of delta fitness scores for mis-
sense variants had a longer positive tail than did nonsense
and synonymous variants, indicating that the fitness of
some missense variants was substantially increased by ele-
vated levels of vitamin B6 (Fig. 1d).
Given a critical mass of experimental variant effect
measurements, missing data can be imputed with accur-
acy approaching that of experimental measurement using
a machine learning model [11, 55]. Therefore, we used a
gradient-boosted tree regression model [55–57] to im-
pute missing entries and refine variant scores that were
measured with lower confidence through weighted aver-
aging (see the “Methods” section). When evaluated using
10× cross-validation, the machine learning prediction
achieved a root-mean-squared deviation (RMSD) of 0.28
and a Pearson correlation of 0.64 and 0.63 for the high and
low vitamin B6 conditions, respectively (Additional file 2:
Figure S7A-B). This performance places its quality on par
with the experimental dataset itself (given the amount of
deviation observed when comparing the high-throughput
experimental data against existing low throughput data in
Additional file 2: Figure S4A-D). The machine learning
method thus allowed for the missing 37% and 39% of VE
map scores in the low and high vitamin B6 conditions,
respectively, to be imputed. Experimentally determined
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values were refined, using a weighted average between
experimental and imputed values, with weighting propor-
tional to measurement confidence. Although this refine-
ment step reduced the number of low-confidence variants
(Additional file 2: Figure S7C), the effects of refinement
were overall minimal, as 99% of variants had their scores
adjusted by less than 0.1 (on the scale from 0 to 1 repre-
senting the difference between the average effects of non-
sense and synonymous variants) (Additional file 2: Figure
S7D). As observed previously [11], the most important fea-
tures informing the machine learning method were intrin-
sic to our experimental data: Quality-weighted averages of
the 3 and 4 most closely related amino acid changes (ac-
cording to BLOSUM distance) had the greatest impact,
followed by conservation and biochemical information
(Additional file 2: Figure S7E). Because imputation is largely
derived from averaging experimental measurements for
other variants at the same amino acid position, we note that
even the imputed scores are, in essence, based on
experimental measurements.
The imputation and refinement procedure yielded
complete variant effect maps for CBS under both low and
high vitamin B6 conditions, which in turn enabled a map
of functional remediability of missense variation to differ-
ent vitamin B6 levels (see the “Methods” section; Fig. 2a, b;
Additional file 3). For comparison, the pre-imputation ver-
sion of the maps is shown in Additional file 2: Figure S8.
The “delta” map, measuring high vitamin B6 − low
vitamin B6 fitness, showed that a substantial fraction of
missense variants have increased activity at an elevated
vitamin B6 level. To better understand the mechanisms
of vitamin B6 remediation, we examined the low vitamin
B6 map to identify variants with fitness scores that
were significantly worse than the fitness distribution
of synonymous variants (see the “Methods” section;
Additional file 2: Figure S9A). Variants that were dele-
terious under low vitamin B6 conditions were then
classified as vitamin B6-remediable or non-remediable
according to whether their delta fitness score signifi-
cantly deviated from the distribution of delta scores
for nonsense variants (see the “Methods” section;
Additional file 2: Figure S9B).
To examine the effects of imputation on delta scores,
we separately examined distributions of delta scores for
the 64.7% of variants for which neither high nor low
vitamin B6 score was imputed, the 6.6% where one of
the scores was imputed, and the 28.7% where both
scores were imputed. The involvement of imputation
was associated with an increase in the median delta
score, but the size of these effects were minor (effect
sizes 0.039 and 0.021 for partially and fully imputed
variants, respectively). Moreover, delta scores based on
imputed data showed fewer and less extreme outliers
(Additional file 2: Figure S10).
Finally, we wondered whether variants that introduce
amino acid changes equivalent to the orthologous S. cer-
evisiae sequence showed increased variant fitness due to
improved adaptation to the yeast host environment. We
therefore compared the set of variants equivalent to S.
cerevisiae, C. elegans (worm) and Drosophila melanoga-
ster (fruit fly) residues to a randomly chosen, disjoint set
of control variants (Additional file 2: Figure S11). While
yeast residues did indeed display a significant increase in
median fitness (Mann-Whitney U test, p = 5.23 × 10−11),
so did worm and fly residues (Mann-Whitney U tests,
p = 5.14 × 10−8 and p = 7.21 × 10−12, respectively). More-
over, there was no significant difference between the
median fitness scores of substitutions to the orthologous
yeast, worm, and fly residue. These observations suggest
that, while variants seen in the host species are more
likely to be tolerated, this effect tends to arise from gen-
eral functional conservation rather than host adaptation.
Concordance of maps with biochemical features and
enzymatic activity
The set of CBS variant effect maps were largely consist-
ent with known biochemical and structural features of
the CBS protein. Early truncating stop codon variants
are uniformly deleterious throughout the whole protein
except the small linker region between the catalytic
domain and the C-terminal regulatory domain. These
exceptions are concordant with the previous finding that
truncating variants at amino acid positions 409 and 410
increase CBS basal enzyme activity upon expression in
yeast by removing the C-terminal autoinhibitory domain
[48]; nonsense variants at these positions exhibited slight
“hyper-complementation” in the low vitamin B6 map
(Additional file 2: Figure S8). However, it should be
noted that in humans these variants are likely to be sub-
ject to nonsense-mediated decay (NMD) and therefore
pathogenic [30]. Nonsense variants within the regulatory
domain were largely deleterious, consistent with previ-
ous observations of such truncations resulting in inactive
enzyme [62].
Coloring each residue in the CBS crystal structure
with the median variant fitness at that position shows
that residues in the central PLP-binding catalytic do-
main, and especially those nearest to bound PLP, are
intolerant to variation (Fig. 2c). Positions in the heme-
binding domain are more tolerant to variation compared
to the PLP-binding domain (Mann-Whitney U test, f =
63.68%, p = 2 ⨉ 10−115, Additional file 2: Figures S12 and
S13). However, substitutions of the heme-binding residue
His65 are detrimental (Additional file 2: Figures S8 and
S12). The C-terminal AdoMet-activated repressive domain
is more tolerant to variation (Mann-Whitney U test, f =
69.30%, p < 2.2 ⨉ 10−16, Additional file 2: Figures S12 and
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Fig. 2 An excerpt of the CBS variant effect (VE) maps and accordingly colorized structures of CBS. a A preview of the full map highlighting the
region of the cut-out. A poster-sized version of the entire map can be found in Additional file 2: Figure S12. b A magnified cut-out of the VE
maps for CBS covering amino acid 328–453: fitness landscape with low level (top) and high levels (center) of vitamin B6 and the delta fitness
(high − low vitamin B6) landscape (bottom). In each plot, the first four rows indicate domain annotations, secondary structure, relative solvent
accessibility, and burial in quaternary structure, respectively. The next subpanel summarizes the distribution of fitness scores at each amino acid
position. The bottom subpanel shows fitness scores for each possible amino acid substitution and nonsense mutation. For high and low vitamin
B6 VE maps, a functional score of 0 (blue) corresponds to the median fitness of nonsense variants. A score of 1 (white) corresponds to the
median fitness of synonymous variants. Yellow fields indicate the wildtype amino acid at each position. Gray fields indicate missing data.
Diagonal lines indicate standard error, with crossed out fields marking variants for which standard error exceeded 1. For the delta fitness
landscape (high − low vitamin B6), substitutions were colored red if delta fitness score is positive and blue if negative. c, d Crystal structure of a
CBS dimer with residues colored according to the median variant fitness with low vitamin B6 (c) or the median delta fitness score (d). The CBS
structure shown is based on PDB entry 4L3V [17]
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S13) suggesting that, at least for the yeast strain and growth
media conditions we used, the function of this domain does
not contribute as much to yeast complementation. Intri-
guingly, the map also shows a number of variants in the
regulatory domain with fitness levels greater than the
average synonymous variant. While it is tempting to
hypothesize that these variants disrupt the autoinhibitory
function of the regulatory domain, there is little biochem-
ical evidence supporting this [24, 25].
The well-documented clinical responsiveness to vita-
min B6 has not yet been fully elucidated mechanistically,
but has been proposed to result from a chemical chap-
eroning effect [15, 49]. To better understand the mech-
anistic underpinnings of vitamin B6 remediability of
human CBS variants in the yeast model, we examined
the delta scores resulting from our maps (Fig. 2d) to-
gether with multiple features, including: the fitness score
itself, computationally-predicted binding energy changes,
residue solvent accessibility, and six secondary structure
features. Although one might naively think that variants
that were the most damaging under the low vitamin B6
condition would be easiest to improve, the predicted
change in folding energy (ΔΔG) tended to be smaller for
remediable variants (median ΔΔG was 1.66× higher in
non-remediable variants; Wilcoxon test, p = 5.61 × 10−28;
Additional file 2: Figure S14A). Indeed, substitutions
with modest fitness scores in the low vitamin B6 map
were most likely to be vitamin B6 remediable: While the
median fitness score of non-remediable variants was 0.09,
the median score of remediable variants was 0.22 (p <
9.63 × 10−78), indicating that some residual CBS enzyme
activity is required for rescue via elevated vitamin B6
(Additional file 2: Figure S14B; Fig. 3a). This result is
concordant with clinical observations that 88% of vitamin
B6-responsive homocystinuric patients have appreciable
CBS activity (above 4% that of wildtype; as measured in
patient plasma by LC-MS/MS [63]), while only 9.5% of
vitamin B6-non-responsive patients have appreciable CBS
activity (Fig. 3b; Additional file 4: Table S2, see the section
“Concordance of CBS maps with pathogenicity and clin-
ical phenotypes” for a discussion of patient phenotype pre-
diction.). We found that positions in a beta-strand
secondary structure tended to have lower delta scores,
while residues in 310-helices tended to have higher delta
scores. Both trends were significant (Wilcoxon test; p =
5.45 × 10−19 and p = 0.02, respectively; Additional file 2:
Figure S14C-H) but had small effect size (0.028 and 0.013
difference in median delta scores, respectively). We also
found that vitamin B6-remediable variants tended to have
higher solvent accessibility (median solvent accessibility
was 1.6 times higher in remediable variants; Wilcoxon
test, p = 3.9 × 10−27; Additional file 2: Figure S14I). This is
consistent with a previous hypothesis by Kopecka and col-
leagues that solvent-accessible mutations in CBS are more
correctable by chemical chaperones including vitamin B6
[31]. However, as we previously established [11], solvent
accessibility is also strongly correlated with variant fitness
scores themselves, so that this correlation may just be the
result of common cause.
Based on these results, we examined the known 3D
structure of CBS [17] with respect to spatial clustering
of amino acid positions for remediable variants. We
found that the five amino acids with the highest median
delta scores (Ser50, Phe197, Arg266, Ile289, and Pro312)
were clustered in a region of approximately 28Å diam-
eter on the joint surface of the catalytic domain, and
heme-binding region (Additional file 2: Figure S15).
Interestingly, these most-remediable residues are also in
proximity to Thr53, which features the lowest median
delta score and directly neighbors Cys52, one of the two
Fig. 3 Variant effect maps confirm that vitamin B6 is more likely to remediate the weakest effect variants. a Distributions of low vitamin B6 fitness
scores for variants that were deleterious under the low vitamin B6 condition, separated according to whether or not they were vitamin B6 remediable.
b Plasma CBS activity distributions of vitamin B6-responsive and non-responsive homocystinuria patients (relative to median activity in controls)
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residues coordinating the heme molecule. The consist-
ently negative delta scores in Thr53 may indicate that
the effects of mutations at this residue are exacerbated
by higher vitamin B6 concentrations. Although we can
speculate that the clustering of these residues on a
common surface reflects an as-yet-unknown molecular
interaction interface, we have no independent evidence
for this.
To evaluate the relationship between our fitness scores
and the residual CBS enzymatic activity, we examined a pre-
vious study reporting in vitro catalytic activities for 26 CBS
missense variants expressed in E. coli [23], (Additional file 5:
Table S3). Our fitness scores exhibited a high rank correl-
ation with measured catalytic activity (Spearman ϱ = 0.68),
and activity and fitness scores exhibited a non-linear rela-
tionship as might be expected from theoretical work by Kac-
ser and Burns on the nature of dominant and recessive
alleles [64]. We fit such a curve to relate activity to fitness
score (see the “Methods” section; Additional file 2: Figure
S16) and it was consistent with the recessive behavior
expected for CBS loss-of-function variants. Although this
model failed to fit some outliers, the likelihood of the data
under this fitted model was 2.7 ⨉ 1011 times greater than
the best possible linear fit.
Concordance of CBS maps with pathogenicity and clinical
phenotypes
We next assessed the potential value of our variant effect
maps in identifying pathogenic CBS alleles, in terms of
the trade-off between precision (fraction of predicted
pathogenic variants that are annotated pathogenic) and
recall (fraction of all annotated pathogenic variants that
were correctly predicted). Because of the generally mod-
est fitness scores in the C-terminal regulatory domain,
we examined CBS alleles in the catalytic and regulatory
domain separately. A set of 74 high-confidence disease-
associated missense variants from the CBS mutation
database [22] and 99 rare variants from gnomAD [1, 2]
were collected to evaluate prediction performance (see
the “Methods” section; Additional file 1: Table S1). How-
ever, only 3 of these 74 disease variants were located in
the regulatory domain, making its evaluation more diffi-
cult. In the catalytic domain, distributions of fitness
scores, plotted separately for disease and non-disease
alleles, clearly show that fitness scores from both low
and high vitamin B6 maps can distinguish pathogenic
variants (Fig. 4a, b). We then compared the performance
in terms of area under the precision vs recall curve
(AUPRC) for our two maps with each of three computa-
tional methods (PolyPhen-2, PROVEAN, and CADD)
[58, 59, 65]. Both of the variant effect maps (AUPRC =
0.84 for high vitamin B6; AUPRC = 0.87 for low vitamin
B6) outperformed all three computational methods
(AUPRC = 0.78 for PolyPhen-2; AUPRC = 0.78 for PRO-
VEAN; AUPRC = 0.69 for CADD) (Fig. 4c). At 90% pre-
cision, the low vitamin B6 variant effect map captured
41% of pathogenic variants, while the best-performing
computational method, PROVEAN, captured only 11%
of pathogenic variants. These results essentially agreed
with our previous study of variants in a panel of 21 hu-
man disease genes, which found that yeast complemen-
tation assays tended to detect pathogenic variation with
triple the sensitivity of the best computational methods
[6]. We also evaluated our maps’ performances in the regu-
latory domain, finding performance that was lower than
that of our maps in the catalytic domain, but higher than
computational methods in the regulatory domain
(AUPRC= 0.40 for the low vitamin B6 map; AUPRC= 0.54
for the high vitamin B6 map; AUPRC= 0.32 for PolyPhen-
2; and AUPRC= 0.31 for PROVEAN; Additional file 2:
Fig. 4 CBS variant effect maps (especially the low vitamin B6 map) can successfully distinguish annotated disease-causing variants from other
random “non-disease” variants. a, b Fitness score distributions of disease and non-disease variants with low (a) or high (b) levels of vitamin B6. c
Precision-recall curves for VE map fitness scores and the computational predictors PROVEAN, PolyPhen-2, and CADD capturing ability of each to
discriminate disease from non-disease alleles. VE maps detect many more disease-causing variants at high precision stringency than do any of
the computational methods
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Figure S17). However, no strong conclusions should be
drawn from this analysis of the regulatory domain, given
that only three disease variants in this region are known.
We next wished to test whether performance differed
between purely experimentally determined variant effect
scores and those that were imputed or refined using our
machine learning method. We re-calculated performance
separately for experimental scores (finding AUPRC =
0.836), for imputed values (AUPRC= 0.856), and for
refined values (AUPRC= 0.842; Additional file 2: Figure
S18). Imputed scores slightly exceeded the performance of
experimental scores, which can perhaps be understood by
the fact that these scores are largely driven by averages of
other experimental measurements at the same amino acid
position. However, the performance of experimental, im-
puted, and refined scores was numerically quite similar.
Evaluation against positive and negative reference vari-
ants allowed us to re-state each variant’s fitness score in
terms of a likelihood ratio of pathogenicity. That is, by
examining the distribution of fitness scores in the two
reference sets, we could determine, for each possible
variant, the likelihood of observing a score at least as
low in the positive reference set, as well as the likelihood
of observing a fitness score at least as high in the nega-
tive reference set (Additional file 2: Figure S19A). The
ratio of these two likelihoods (also known as a Bayes
Factor) expresses how much more (or less) likely the
variant is to belong to the positive (presumed disease
causing) set rather than the negative (presumed benign)
set. Using this strategy, we calculated log likelihood ra-
tios (LLRs) for each variant (Additional file 6: Table S4).
The overall distribution of LLRs across all possible
amino acid changes in CBS (Additional file 2: Figure
S19B) shows that 39% of variants are at least 10× more
likely to be pathogenic than benign, while 33% of vari-
ants are at least 10× more likely to be benign than dis-
ease causing. CBS variant LLRs also range further into
the negative values than into positive values: While we
found 15% of variants to be >100× more likely to be
benign than disease causing given the map evidence, no
variants were found to be >100× more likely to be
pathogenic than benign.
Finally, we wished to examine the ability of our maps,
based on complementation phenotypes in yeast, to predict
quantitative human phenotypes. For this purpose, we
examined an evaluation cohort of 29 well-phenotyped
homocystinuria patients (for genotypes and phenotypic
characteristics see Additional file 2: Table S6). Among
these patients, 12 were vitamin B6-non-responsive, 12 fully
or extremely responsive, and 5 partially responsive. Con-
sistent with the established inheritance pattern, all patients
were either homozygous or compound heterozygous for
CBS mutations. Two additional patients, each carrying an
allele in the regulatory domain (p.Trp409*; p.Asp444Asn),
were not evaluated because the yeast complementation
assay did not appear sufficiently sensitive to perturbation
in the regulatory domain (see details in the “Discussion”
section). Of the 29 remaining patients, 20 had a genotype
involving the allele p.Ile278Thr, thus introducing a poten-
tial bias from a single recurrent variant. Therefore, we
used an objective protocol to iteratively eliminate pa-
tients from the analysis to limit the recurrence of indi-
vidual variants (see the “Methods” section and
Additional file 7: Table S5).
Based only on a list of the remaining alleles (blinded
to phenotypes), we first retrieved each allele’s imputed
low and high vitamin B6 variant effect map score and
calculated diploid scores for each patient by treating
variant fitness scores as additive in trans and multiplica-
tive in cis (see the “Methods” section for more details).
Three patient CBS activity scores were calculated, corre-
sponding to the low vitamin B6, high vitamin B6, and
differential (high − low vitamin B6) maps. Correlation
was examined for each type of patient activity score
between each of three clinical phenotypes: age of onset,
disease severity, and clinical response to vitamin B6
(Fig. 5).
Patient scores derived from the low vitamin B6 map
yielded strong correlations with patient phenotypes that
were highly significant: Correlations in terms of Spearman’s
ϱ were 0.71 (p = 0.05), 0.86 (p = 0.003), and 0.93 (p = 9.91 ×
10−5) for age of onset, disease severity, and clinical vitamin
B6 response, respectively. The high vitamin B6 CBS scores
correlated just as strongly, with Spearman’s ϱ = 0.71 (p =
0.05), 0.86 (p = 0.003), and 0.93 (p = 9.91 × 10−5) for age of
onset, disease severity, and vitamin B6 responsiveness, re-
spectively. The differential (high − low vitamin B6) diploid
scores showed a weaker correlation at ϱ = 0.56 (p = 0.14),
0.8 (p = 0.009), and 0.84 (p = 0.002) for age of onset, disease
severity, and vitamin B6 responsiveness, respectively. All
map-based scores performed better than the computational
method PROVEAN [59], which in the previous analysis
was the best-performing computational method for patho-
genicity classification (see above). PROVEAN yielded very
poor correlations of ϱ = 0.44 (p = 0.27), 0.59 (p = 0.09), and
0.64 (p = 0.05) for age of onset, disease severity, and clinical
vitamin B6 response, respectively. In the interest of
completeness, an unfiltered version of this analysis
with all 29 patients (which may heavily be skewed by
our performance for recurrent variants) is also shown
in Additional file 2: Figure S20.
In summary, variant effect maps based on experi-
mental measurements of the growth of yeast cells ex-
pressing human CBS gene variants, without any
further computational fitting or calibration based on
human traits, yielded diploid scores that strongly cor-
related with clinical phenotypes in patients with clas-
sical homocystinuria.
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Discussion
Here we generated proactive maps of the effects of
missense variation in the human CBS gene. Using
codon-randomizing mutagenesis to generate a clone li-
brary bearing nearly 80% of all possible amino acid
changes, we measured the functional consequences of
CBS variation by measuring the effects of selection on
allele frequencies during a competitive yeast comple-
mentation assay using next-generation sequencing. The
resulting proactive variant effect maps agreed closely
with the results of single-variant assays, and the map for
low vitamin B6 levels showed especially high perform-
ance in identifying pathogenic variants.
A machine learning model was used to impute missing
data and refine the maps, with performance in identifying
disease variants that was on par with (even slightly
exceeding) direct experimental measurement. Although
this was initially surprising, it is perhaps more intuitive
when one considers that imputation was largely driven by
averages of experimental measurements of other substitu-
tions at the same amino acid position.
Overall, we found that our CBS variant effect map
could accurately distinguish annotated pathogenic vari-
ants from unannotated variants. At a stringent threshold
achieving 90% precision in our test set, the variant effect
map captured more than twice the number of patho-
genic variants than did the best-performing computa-
tional prediction method at the same 90% precision
stringency.
An important caveat to our maps is that, because the
underlying complementation assay is based on expres-
sion of mature cDNA, they cannot detect the impact of
Fig. 5 CBS VE maps, which have not been trained on patient data, successfully predict patient phenotype and response to vitamin B6 therapy. a–
d Correlation between diploid VE map or PROVEAN scores and age of onset. e–h Correlation between diploid VE map or PROVEAN scores and
disease severity scores. i–l Correlation between diploid VE map or PROVEAN scores and clinical vitamin B6 response. Degree of disease severity:
5 = no symptoms at the time of diagnosis, 4 =mild disease, 3 =moderate disease, 2 = borderline severity, 1 = severe disease. Degree of vitamin B6
responsiveness: 1 = non-responsive, 2 = partial responsive, 3 = fully responsive, 4 = extremely pyridoxine responsive. A small amount of random
noise (jitter) was added to the categorical values of disease severity and vitamin B6 responsiveness to visually separate coincident data points. The
amount of random noise is uniformly distributed in the interval [0;0.2]. Vertical lines connect data points with identical genotypes
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variants on splicing. Also, some pathogenic variants such
as p.Trp409Ter, which in humans would be subject to
NMD, were not detected as damaging in our assay.
Furthermore, our assay measures protein function in the
context of the cellular machinery in the yeast host.
Therefore, the assay can miss the functional impact of
variants that perturb molecular functions that are im-
portant in human cells but not relevant in yeast. In the
case of CBS, the function of the AdoMet-binding regula-
tory domain appeared less important than the catalytic
domain to functional complementation, as variants in
this domain were generally more likely to be tolerated in
our assay. Therefore, our assay may be unsuitable for
detecting some pathogenic variants in this regulatory
domain (e.g., p.Asp444Asn). Further complicating vari-
ant interpretation, a number of variants in the regulatory
domain have previously been observed to render CBS
biochemically hyperactive and yet paradoxically cause
symptoms typical for CBS deficiency [15, 24–26, 63].
Nevertheless, most truncating variants falling within the
regulatory domain did behave like null variants suggest-
ing that our assay can still capture some large-effect
variants in this domain. Given the uncertainty, however,
we excluded CBS alleles in the C-terminal regulatory do-
main when evaluating the ability of our maps to infer
patient phenotypes.
In addition to systematic error, our measurements
are also subject to random error. We previously eval-
uated this aspect of the methodology [11]. Briefly, a
relationship exists between the frequency of the vari-
ant in the library (as measured by read count) and
the magnitude of noise potentially affecting the measure-
ment. An analysis of this relationship was incorporated into
a Bayesian error regularization procedure (described in the
“Methods” section) to improve our error estimates.
Another source of random noise was introduced by the dif-
ferent in cis genotypic backgrounds in which each variant
can appear. TileSeq measures the log of the ratio of each
variant’s marginal frequency (i.e., neglecting in cis variant
context) in the selective condition relative to its marginal
frequency in the non-selective condition. These log-ratio
scores are subsequently calibrated using the distribution of
log-ratio scores of synonymous variants, so that accurate
scoring requires that in cis variants will, on average, have
the same effect on log-ratio scores of the variant of interest
as they will on synonymous variants. Therefore, noise will
rise as the fraction of clones with in cis variants rises, as the
fraction of in cis variants with functional effects rises, and
fall as the diversity of in cis variants rises. To efficiently con-
vey these caveats to the user, we provided estimates of un-
certainty for experimental, imputed, and refined map
scores and for the Bayes’ factors (LLRs) that we provided to
incorporate our results into a Bayesian framework for vari-
ant interpretation.
There are also important caveats in the variant sets we
used for evaluations. Given the lack of rare missense
variants that have been annotated as “likely benign” or
“benign” in ClinVar, we instead used gnomAD variants
(after excluding known or suspected pathogenic vari-
ants) as a negative reference set. Although it cannot be
guaranteed that all underlying individuals are indeed
symptom-free, variants in this set can at least be ex-
pected to be strongly enriched for benign cases, render-
ing it an acceptable choice in the absence of alternatives.
Another caveat for our predictions of pathogenicity,
which applies more broadly to all clinical annotations of
variant pathogenicity, is that variants established as
pathogenic in one context may not be pathogenic in
every patient. This could stem from the recessive nature
of a trait or from sources of incomplete penetrance or
variable expressivity such as environmental effects,
stochastic developmental effects, or modifier alleles. To
partially address only the issue of recessiveness, we used
our maps to score diploid genotypes of patients with
homocystinuria (Fig. 5).
Despite the inherent challenges of predicting clinical
phenotypes in diploid humans, our patient CBS activity
scores, derived from variants that had been individually
assessed in a haploid yeast model, correlated significantly
with age of disease onset and with disease severity.
Although these correlations were not perfect, they
should be considered in the context that different pa-
tients who are homozygous for the same variant exhibit
wide phenotypic expression [66]. Moreover, the need to
reduce bias from recurrent variants meant that our cor-
relations were based on observations from only 7 unique
diploid genotypes (involving 11 unique haploid geno-
types) from an original set of 29 patients. Given these
challenges, we consider it to be surprising that we
achieved significant correlation with patient phenotypes
for all three phenotypes from measurements in yeast,
and especially noteworthy that map-derived activity
scores could strongly predict patient responsiveness to
vitamin B6 supplementation. Performance might be im-
proved further by testing allele combinations in a
compound-heterozygous diploid model system.
We made many observations that could be explored
further in the future. For example, the variants in the
regulatory domain which appeared to grow faster than
the wildtype control in the complementation assay. It is
conceivable that some of these variants interfere with
the autoinhibitory function of the domain and thus
increase the biochemical activity of CBS. However, as
mentioned above, biochemical hyperactivity due to loss
of autoinhibition may have unexpected physiological
consequences.
Despite the ability of cell-based complementation as-
says to detect deleterious variants with high accuracy,
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additional context will be required to explain the mech-
anism of defects. For example, it is unclear whether pro-
tein function has been reduced due to a direct reduction
in enzymatic activity, disruption of the ability to receive
an activating modification, or due to misfolding that re-
duces stability and leads to a lower steady-state protein
expression level. There is now ample precedent for VE
maps that measure the effect of variation on “sub-func-
tions” such as protein-protein interaction (which might
include tetramerization for CBS), protein abundance, or
post-translational modification [5, 9, 67].
The clinical complications of CBS deficiency can be
reduced dramatically if the diagnosis is made shortly
after birth and if treatment is started in early infancy
[35]. Many cases of CBS deficiency can be identified
through population-level screening in newborns based
on methionine levels and/or methionine/phenylalanine
ratios which are usually elevated in severe vitamin B6-
non-responsive forms of homocystinuria [43, 44]. Unfor-
tunately, the majority of vitamin B6-responsive patients
assessed in newborn screening programs for elevated
methionine are missed due to the absence of this bio-
chemical trait [43, 44]. Although CBS deficiency can be
diagnosed later in childhood upon presentation with
classical (and irreversible) symptoms of lens dislocation,
skeletal abnormalities, thromboembolism, and cognitive
impairment, many vitamin B6-responsive patients do not
present until adulthood [35].
The CBS VE maps we provide could have future value
in at least three clinical scenarios. First, the ever-growing
use of sequencing in routine genetic care may identify
variants of uncertain significance (VUS) in symptomatic
patients for whom homocystinuria is not strongly
suspected (e.g., in patients with cognitive defects or con-
nective tissue disorders, for which many causes are pos-
sible a priori). In this scenario, genomic sequencing
coupled with the VE map could sensitively detect dele-
terious CBS variants and thus trigger tHcy measurement
and further confirmatory testing, while reducing false
positives.
The second scenario for potential clinical use involves
patients with suspected CBS deficiency and grossly ele-
vated homocysteine levels. In these patients, CBS gene
sequencing may identify variants that are unclassified or
currently classified as VUS. Because elevated homocyst-
eine can be caused by a number of factors [68] and
enzymatic confirmation of CBS deficiency is available in
only a few laboratories worldwide, functional informa-
tion from the VE map could enable clinical interpret-
ation of pathogenicity and thus aid in clinical diagnosis.
Third, should population-level newborn genome se-
quences become available in the future, genome interpret-
ation using the CBS variant effect map has potential value,
even in the absence of elevated methionine or early
childhood symptoms. Interpretation of detected CBS vari-
ants, informed by the VE map, could potentially trigger
tHcy measurement. Subsequent detection of elevated tHcy
could, with further confirmatory testing, identify additional
cases of CBS deficiency, particularly those that would be
most responsive to vitamin B6 therapy (Additional file 2:
Figure S21).
There are 497 human genes that encode a cofactor-
dependent enzyme, of which at least 193 (39%) reportedly
harbor disease-causing variants [69, 70] (Additional file 8 :
Table S6). Based on overall rates of missense variation
[71, 72], we might expect every individual to carry
roughly 5–10 missense alleles in these enzymes on
average. We recently performed a survey of assayable
genes [11], finding that 53% of genes have assays tract-
able for VE mapping and ~ 10% have a yeast comple-
mentation assay.
Conclusions
Our study provides a blueprint for systematic proactive
experimental evaluation of missense variant effects on hu-
man enzymes using cell-based models, including experi-
mental modeling of how the impact of variants depends
on therapeutic context. Our study also offers an example
of how variant effect maps derived from cell-based assays
can be exploited to estimate quantitative human pheno-
types and therapeutic outcomes from personal genome
information.
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